{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:20:05Z","timestamp":1761060005429},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Cochin-Port Royal Hospital, Medical Oncology Department and Haematology Department"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00280-015-2875-8","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T05:54:36Z","timestamp":1443506076000},"page":"1033-1039","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters"],"prefix":"10.1007","volume":"76","author":[{"given":"Zahra","family":"Ajgal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Emile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatole","family":"Cessot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marie","family":"Tigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascaline","family":"Boudou-Rouquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Fontenay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"issue":"6 Suppl 13","key":"2875_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","volume":"31","author":"TM Allen","year":"2004","unstructured":"Allen TM, Francis JM (2004) Advantages of Liposomal Delivery Systems for Anthracyclines. Semin Oncol 31(6 Suppl 13):5\u201315","journal-title":"Semin Oncol"},{"issue":"3","key":"2875_CR2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1634\/theoncologist.2007-0180","volume":"13","author":"WC Zamboni","year":"2008","unstructured":"Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13(3):248\u2013260. doi: 10.1634\/theoncologist.2007-0180","journal-title":"Oncologist"},{"issue":"2","key":"2875_CR3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/08982104.2010.496085","volume":"21","author":"WC Zamboni","year":"2011","unstructured":"Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J et al (2011) Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 21(2):158\u2013165. doi: 10.3109\/08982104.2010.496085","journal-title":"J Liposome Res"},{"issue":"20","key":"2875_CR4","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323\u20133329. doi: 10.1200\/JCO.2009.25.7519","journal-title":"J Clin Oncol"},{"issue":"18","key":"2875_CR5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, Keating GM (2011) Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma. Drugs 71(18):2531\u20132558. doi: 10.2165\/11207510-000000000-00000","journal-title":"Drugs"},{"issue":"3","key":"2875_CR6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ijcard.2012.10.079","volume":"167","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Palazzoni G, Abbate A, De Marco E, Mezzaroma E, Di Persio S, Frati G, Loperfido F, Biondi-Zoccai G (2013) Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (liposomal doxorubicin-investigational chemotherapy-tissue doppler imaging evaluation) randomized pilot study. Int J Cardiol 167(3):1055\u20131057. doi: 10.1016\/j.ijcard.2012.10.079","journal-title":"Int J Cardiol"},{"issue":"27","key":"2875_CR7","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","volume":"27","author":"JA Sparano","year":"2009","unstructured":"Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OL, Bondarenko IN, Bogdanova NV et al (2009) Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27(27):4522\u20134529. doi: 10.1200\/JCO.2008.20.5013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2875_CR8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","volume":"9","author":"G Berry","year":"1998","unstructured":"Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9(7):711\u2013716","journal-title":"Ann Oncol"},{"issue":"7","key":"2875_CR9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Ann Oncol 18(7):1159\u20131164. doi: 10.1093\/annonc\/mdl477","journal-title":"Ann Oncol"},{"issue":"14","key":"2875_CR10","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"1","key":"2875_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","volume":"69","author":"NM La-Beck","year":"2012","unstructured":"La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69(1):43\u201350. doi: 10.1007\/s00280-011-1664-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2875_CR12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00280-014-2378-z","volume":"73","author":"M Gusella","year":"2014","unstructured":"Gusella M, Bononi A, Modena Y, Bertolaso L, Franceschetti P, Menon D, Pezzolo E et al (2014) Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old. Cancer Chemother Pharmacol 73(3):517\u2013524. doi: 10.1007\/s00280-014-2378-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2875_CR13","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","volume":"118","author":"KL Wong","year":"2011","unstructured":"Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC (2011) Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118(5):e16\u2013e31. doi: 10.1182\/blood-2010-12-326355","journal-title":"Blood"},{"issue":"11","key":"2875_CR14","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","volume":"22","author":"JE Kurtz","year":"2011","unstructured":"Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Intergroup Gynecologic Cancer et al (2011) Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol Off J Eur Soci Med Oncol ESMO 22(11):2417\u20132423. doi: 10.1093\/annonc\/mdr001","journal-title":"Ann Oncol Off J Eur Soci Med Oncol ESMO"},{"issue":"3","key":"2875_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ygyno.2013.09.031","volume":"131","author":"EM Ko","year":"2013","unstructured":"Ko EM, Lippmann Q, Caron WP, Zamboni W, Gehrig PA (2013) Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecol Oncol 131(3):683\u2013688. doi: 10.1016\/j.ygyno.2013.09.031","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2875_CR16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2009.04.007","volume":"114","author":"JL Tanyi","year":"2009","unstructured":"Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK (2009) Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 114(2):219\u2013224. doi: 10.1016\/j.ygyno.2009.04.007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2875_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2006.01.031","volume":"103","author":"ME Gordinier","year":"2006","unstructured":"Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO (2006) Elevated body mass index does not increase the risk of palmar\u2013plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecol Oncol 103(1):72\u201374. doi: 10.1016\/j.ygyno.2006.01.031","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2875_CR18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","volume":"5","author":"S Gordon","year":"2005","unstructured":"Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12):953\u2013964. doi: 10.1038\/nri1733","journal-title":"Nat Rev Immunol"},{"key":"2875_CR19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","volume":"27","author":"C Auffray","year":"2009","unstructured":"Auffray C, Sieweke MH, Geissmann F (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27:669\u2013692. doi: 10.1146\/annurev.immunol.021908.132557","journal-title":"Annu Rev Immunol"},{"issue":"7355","key":"2875_CR20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222\u2013225. doi: 10.1038\/nature10138","journal-title":"Nature"},{"issue":"7446","key":"2875_CR21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW (2013) Origins and hallmarks of macrophages: development, homeostasis, and disease. Nature 496(7446):445\u2013455. doi: 10.1038\/nature12034","journal-title":"Nature"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2875-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2875-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:38Z","timestamp":1559023658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2875-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2875-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}